Open AccessEvaluation of the Efficiency of Treatment with Rituximab for Systemic Scleroderma (A Case Report)
Author(s) -
E. N. Harlamova,
Ju. Ju. Karpenko
Publication year - 2021
Publication title -
arhivʺ vnutrennej mediciny
Language(s) - English
Resource type - Journals
eISSN - 2411-6564
pISSN - 2226-6704
DOI - 10.20514/2226-6704-2021-11-1-72-75
Subject(s) - medicine , rituximab , scleroderma (fungus) , systemic scleroderma , disease , systemic therapy , progressive systemic sclerosis , stage (stratigraphy) , dermatology , oncology , immunology , antibody , cancer , paleontology , inoculation , breast cancer , biology
The article describes a clinical case of a progressive form of systemic scleroderma in a 39-year-old man. The patient has an acute course and rapid progression of the disease with a significant initial decrease in the forced vital capacity of the lungs, with signs of an unfavorable prognosis, such as a diffuse form, a high skin count (> 14), male sex, and high positivity for antibodies to Scl-70. In connection with the ineffectiveness of standard therapy with glucocorticoids and immunosuppressants at an early stage of the disease, the option of treatment with genetically engineered drugs (rituximab) was considered. As a result of the therapy, a positive trend was noted.